
Girumsew Wendmagegn
Examiner (ID: 176, Phone: (571)270-1118 , Office: P/2484 )
| Most Active Art Unit | 2484 |
| Art Unit(s) | 2621, 2484 |
| Total Applications | 1118 |
| Issued Applications | 807 |
| Pending Applications | 62 |
| Abandoned Applications | 276 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16913830
[patent_doc_number] => 20210186922
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => METHODS AND COMPOSITIONS FOR REDUCING EPIGENETIC AGE AND MITOCHONDRIAL DYSFUNCTION
[patent_app_type] => utility
[patent_app_number] => 17/176305
[patent_app_country] => US
[patent_app_date] => 2021-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12784
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17176305
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/176305 | Compositions for promoting the endogenous self-renewal of stem cells | Feb 15, 2021 | Issued |
Array
(
[id] => 16805951
[patent_doc_number] => 20210128504
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/126787
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28866
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17126787
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/126787 | Autoimmune disorder treatment using RXR agonists | Dec 17, 2020 | Issued |
Array
(
[id] => 16805950
[patent_doc_number] => 20210128503
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/126714
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28865
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17126714
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/126714 | Autoimmune disorder treatment using RXR agonists | Dec 17, 2020 | Issued |
Array
(
[id] => 16466615
[patent_doc_number] => 20200368152
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => LIQUID DEPOT FOR NON-INVASIVE SUSTAINED DELIVERY OF AGENTS TO THE EYE
[patent_app_type] => utility
[patent_app_number] => 16/909242
[patent_app_country] => US
[patent_app_date] => 2020-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14265
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16909242
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/909242 | Liquid depot for non-invasive sustained delivery of agents to the eye | Jun 22, 2020 | Issued |
Array
(
[id] => 16359283
[patent_doc_number] => 20200316034
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-08
[patent_title] => ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/905059
[patent_app_country] => US
[patent_app_date] => 2020-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11300
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 205
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16905059
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/905059 | Anhydrous compositions of mTOR inhibitors and methods of use | Jun 17, 2020 | Issued |
Array
(
[id] => 16189283
[patent_doc_number] => 20200230132
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-23
[patent_title] => METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVE
[patent_app_type] => utility
[patent_app_number] => 16/722816
[patent_app_country] => US
[patent_app_date] => 2019-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18044
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16722816
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/722816 | METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVE | Dec 19, 2019 | Abandoned |
Array
(
[id] => 15797007
[patent_doc_number] => 20200121646
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-23
[patent_title] => CHEMICAL COMPOSITIONS AND METHODS FOR ENHANCING TRANSDERMAL DELIVERY OF THERAPEUTIC AGENTS
[patent_app_type] => utility
[patent_app_number] => 16/716857
[patent_app_country] => US
[patent_app_date] => 2019-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8778
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16716857
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/716857 | CHEMICAL COMPOSITIONS AND METHODS FOR ENHANCING TRANSDERMAL DELIVERY OF THERAPEUTIC AGENTS | Dec 16, 2019 | Abandoned |
Array
(
[id] => 15649575
[patent_doc_number] => 20200087317
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-19
[patent_title] => Prodrugs of Secondary Amine Compounds
[patent_app_type] => utility
[patent_app_number] => 16/562698
[patent_app_country] => US
[patent_app_date] => 2019-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12801
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 118
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16562698
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/562698 | Prodrugs of secondary amine compounds | Sep 5, 2019 | Issued |
Array
(
[id] => 15035407
[patent_doc_number] => 20190328708
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-31
[patent_title] => METHOD FOR ADMINISTRATION
[patent_app_type] => utility
[patent_app_number] => 16/510256
[patent_app_country] => US
[patent_app_date] => 2019-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2848
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16510256
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/510256 | METHOD FOR ADMINISTRATION | Jul 11, 2019 | Abandoned |
Array
(
[id] => 15990195
[patent_doc_number] => 20200170968
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-04
[patent_title] => Use of N-Acetylcysteine Amide in the Treatment of Acquired Immune Deficiency Syndrome and HIV Infection
[patent_app_type] => utility
[patent_app_number] => 16/502297
[patent_app_country] => US
[patent_app_date] => 2019-07-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5458
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16502297
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/502297 | Use of N-Acetylcysteine Amide in the Treatment of Acquired Immune Deficiency Syndrome and HIV Infection | Jul 2, 2019 | Abandoned |
Array
(
[id] => 15290541
[patent_doc_number] => 20190388406
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-26
[patent_title] => METHODS OF PREVENTION AND TREATMENT OF THROMBOSIS
[patent_app_type] => utility
[patent_app_number] => 16/427209
[patent_app_country] => US
[patent_app_date] => 2019-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7642
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16427209
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/427209 | METHODS OF PREVENTION AND TREATMENT OF THROMBOSIS | May 29, 2019 | Abandoned |
Array
(
[id] => 15178045
[patent_doc_number] => 20190359614
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-28
[patent_title] => PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 16/404601
[patent_app_country] => US
[patent_app_date] => 2019-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13864
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16404601
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/404601 | Purine derivatives for the treatment of viral infections | May 5, 2019 | Issued |
Array
(
[id] => 15083303
[patent_doc_number] => 20190336462
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-07
[patent_title] => USE OF HYDROGEN SULFIDE SYNTHESIS INHIBITORS FOR CANCER THERAPY
[patent_app_type] => utility
[patent_app_number] => 16/392022
[patent_app_country] => US
[patent_app_date] => 2019-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13214
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16392022
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/392022 | USE OF HYDROGEN SULFIDE SYNTHESIS INHIBITORS FOR CANCER THERAPY | Apr 22, 2019 | Abandoned |
Array
(
[id] => 15616115
[patent_doc_number] => 20200078462
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-12
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 16/388535
[patent_app_country] => US
[patent_app_date] => 2019-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13403
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16388535
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/388535 | Pharmaceutical compositions comprising POH derivatives | Apr 17, 2019 | Issued |
Array
(
[id] => 15615901
[patent_doc_number] => 20200078355
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-12
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 16/384534
[patent_app_country] => US
[patent_app_date] => 2019-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11133
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16384534
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/384534 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Apr 14, 2019 | Abandoned |
Array
(
[id] => 14581095
[patent_doc_number] => 20190218156
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-18
[patent_title] => AGONIST/ANTAGONIST COMPOSITIONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/359931
[patent_app_country] => US
[patent_app_date] => 2019-03-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9892
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16359931
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/359931 | AGONIST/ANTAGONIST COMPOSITIONS AND METHODS OF USE | Mar 19, 2019 | Abandoned |
Array
(
[id] => 14464299
[patent_doc_number] => 20190183789
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-06-20
[patent_title] => INTRAVASCULAR DELIVERY OF NANOPARTICLE COMPOSITIONS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/284995
[patent_app_country] => US
[patent_app_date] => 2019-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15909
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16284995
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/284995 | INTRAVASCULAR DELIVERY OF NANOPARTICLE COMPOSITIONS AND USES THEREOF | Feb 24, 2019 | Abandoned |
Array
(
[id] => 14990789
[patent_doc_number] => 20190314352
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-17
[patent_title] => ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/277537
[patent_app_country] => US
[patent_app_date] => 2019-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14421
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16277537
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/277537 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | Feb 14, 2019 | Abandoned |
Array
(
[id] => 16769690
[patent_doc_number] => 10980772
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-04-20
[patent_title] => Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
[patent_app_type] => utility
[patent_app_number] => 16/272328
[patent_app_country] => US
[patent_app_date] => 2019-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 12069
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16272328
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/272328 | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies | Feb 10, 2019 | Issued |
Array
(
[id] => 14406547
[patent_doc_number] => 20190169117
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-06-06
[patent_title] => TOPICAL COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/269318
[patent_app_country] => US
[patent_app_date] => 2019-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10867
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16269318
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/269318 | Topical compositions for the treatment of dermatological disorders | Feb 5, 2019 | Issued |